Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02603055
Other study ID # JSVCT025
Secondary ID
Status Completed
Phase Phase 1
First received November 10, 2015
Last updated August 30, 2016
Start date July 2015
Est. completion date August 2016

Study information

Verified date August 2016
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Hepatitis E is characteristic by sporadic and local epidemic around the world, and mainly infects adults aged 15 to 40 years old, resulting in the infection rate ranged from 1% to 15%. The investigational hepatitis E vaccine is a recombinant aluminium-adjuvant hepatitis E vaccine.

This is a single center, randomized, blinding, parallel-controlled phase Ib clinical trial. This study will determine the safety and immunogenicity of the investigational recombinant hepatitis E vaccine in healthy adults between 16 and 65 years.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 16 Years to 65 Years
Eligibility Inclusion Criteria:

- Aged between 16 and 65 years with normal intelligence.

- Negative in antibody against hepatitis E test.

- No plan to go out for a long time within 9 months.

- Able to understand the content of informed consent and willing to sign the informed consent

- General good health as established by medical history and physical examination.

- Able and willing to complete all the secluded study process during the whole study follow-up period.

- No history of hepatitis B, hepatitis C and hepatitis E(Patients diagnosed as hepatitis B, hepatitis C and hepatitis E by town or above)

- Axillary temperature =37.0°C on the day of enrollment

Exclusion Criteria:

- Woman who is pregnant, breast-feeding or planning to be pregnant during the study period

- Allergic history of any vaccination or drugs, or allergic to any ingredient of the Hepatitis E vaccine

- History of serious adverse reactions after vaccination, such as allergies, urticaria, breathing difficulties, angioneurotic oedema or abdominal pain

- Autoimmune disease or immunodeficiency

- Asthma that was unstable and need emergency treatment, hospitalization, oral or intravenous corticosteroid within two years

- Type I or II diabetes, not including gestational diabetes

- History of thyroidectomy, or need treatment for thyroid disease in the past 12 months

- History of serious angioneurotic edema in the past 3 years, or need treatment for it in the past 2 years

- Severe hypertension, with the blood pressure still more than 150/100 mmHg after drug maintenance treatment

- Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders, platelet abnormalities) or coagulation disorders diagnosed by the doctor.

- Patients who are active or not have a definite cure of malignant tumors, or who may recur in the study period.

- Epilepsy, not including alcohol epilepsy in the first 3 years abstinence or simple epilepsy without the need of treatment in the past 3 years

- Asplenia or functional asplenia, or asplenia and splenectomy under any circumstances

- Guillain Barre Syndrome

- Prior administration of immunodepressant, cytotoxic or corticosteroids (not including corticosteroid therapy for allergic rhinitis and acute non concurrent dermatitis )treatment in last 6 months

- Prior administration of immune globulin in last 3 months

- Prior administration of other research medicines in last 1 month

- Prior administration of attenuated vaccine in last 1 month

- Prior administration of subunit or inactivated vaccine in last 14 days, such as pneumococcal Vaccine

- Current anti-tuberculosis prophylaxis or therapy

- Fever (axillary temperature 38.0?) in 3 days before vaccination or any acute disease, systemic application of antibiotics or antiviral therapy in the past five days

- Unable to comply with the study requirements due to the psychological situation, a past or present history of mental disease, two-stage affective psychosis which were not well controlled in the past two years; mental disease need medical treatment, and have suicidal tendency over the past five years

- Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
30µg/0.5ml Hepatitis E vaccine
three doses, 30µg/0.5ml per dose
30µg/0.5ml Recombinant Hepatitis E vaccine
30µg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30µg/0.5ml per dose

Locations

Country Name City State
China Jiangsu Provincial Center for Diseases Control and Prevention Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention Changchun Institute of Biological Products Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of adverse reactions after vaccination Occurrence of adverse reactions within 7 days after each vaccination with the Recombinant Hepatitis E vaccine. within 7 days after each vaccination Yes
Primary The geometric mean concentration of antibody against Hepatitis E responses to the Hepatitis E vaccine Antibody against Hepatitis E responses to the Hepatitis E vaccine at 7 months after the first vaccination 7 months after the first vaccination No
Secondary Occurrence of adverse events after each vaccination Occurrence of adverse events within 28 days after each vaccination with the Hepatitis E vaccine. within 28 days after each vaccination Yes
Secondary Occurrence of serious adverse events after the vaccination. Occurrence of serious adverse events within 12 months after the first vaccination with the Hepatitis E vaccine. within 12 months after the first vaccination Yes
Secondary The positive rates of antibody against Hepatitis E responses to the Hepatitis E vaccine. The positive rates of antibody against Hepatitis E responses to the Hepatitis E vaccine at 7 months after the first vaccination. 7 months after the first vaccination No
See also
  Status Clinical Trial Phase
Completed NCT03365921 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial) Phase 4
Completed NCT02584543 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine) Phase 4
Not yet recruiting NCT03488589 - HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Completed NCT03601221 - Seroprevalence Hepatitis E Infection in Healthy Blood Donors
Completed NCT03168412 - A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule) Phase 4
Completed NCT02189603 - Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Phase 4
Completed NCT02847507 - Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
Completed NCT02190253 - Seroprevalence of Hepatitis E in People With an Organ Transplant
Recruiting NCT06457438 - Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors N/A
Completed NCT04670419 - Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
Completed NCT03282474 - HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE) Phase 2
Terminated NCT02558114 - Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection. Phase 4
Recruiting NCT06137313 - Exposure to Hepatitis E Virus in Occitania, France
Completed NCT02964910 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients ) Phase 4
Completed NCT01014845 - Clinical Trial of Recombinant Hepatitis E Vaccine Phase 3
Recruiting NCT05976594 - Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
Completed NCT02417597 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli) Phase 4
Completed NCT03827395 - Safety Study of Hepatitis E Vaccine (HEV239) Phase 1